All News
Activity & Pain Tolerance (3.29.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, including where you should sit in clinic and why you should worry about secondary Sjogren's in RA.
Read Article
7 Updates on Prosthetic Joint Infections
These are excerpts and takeaway summaries from several literature reports addressing the diagnosis and outcomes of prosthetic joint infections (PJI).
Read Article
Systemic Score Predicts Still's Disease Severe Complications
A multinational study of adults with Still's disease found that calculating their systemic score at baseline significantly predicted the patients risk for life-threatening outcomes (MAS or death).
GEM: Dysphagia in myositis pts is from skeletal muscle involvement, causing upper pharyngeal dysphagia, but may also manifest as dysphonia, nasal regurgitation, or aspiration (w/ risk of pneumonia). https://t.co/MOyfdCJywC
Dr. John Cush RheumNow ( View Tweet)
Cabaletta Bio announced FDA has granted Orphan Drug Designation to CABA-201, a 4-1BB-containing human CD19-CAR T cell agent, to treat systemic sclerosis. RESET (REstoring SElf-Tolerance) trial program includes the Phase 1/2 RESET-SSc trial https://t.co/Vo5jIHBrPj https://t.co/TXvFypbZdw
Dr. John Cush RheumNow ( View Tweet)
Secondary Sjogren’s Ups Rheumatoid Arthritis Severity
A Swiss observational study has shown that RA patients with concomitant Sjögren’s disease (SjD) are more likely to have a severe RA phenotype, and be less responsive to treatment.
https://t.co/4dcackIe4S https://t.co/5VZ9I7r29F
Dr. John Cush RheumNow ( View Tweet)
Autoimmune dz pts have higher risk of macular degeneration. Cleveland Clinic study of 200K AMD vs controls, finds:
- SLE (RR 1.73)
- Scleroderma (1.65)
- Psoriasis (1.48)
- Vasculitis (1.48)
- RA (1.4)
- UC &CD (~1.42)
- Sarcoid (1.42) https://t.co/RrXaaqz3Aw https://t.co/9dGoGRCBYu
Dr. John Cush RheumNow ( View Tweet)
2023 EULAR Psoriatic Arthritis Recommendations
EULAR has updated its treatment recommendations— The updated guidance includes 7 overarching principles and 11 recommendations regarding treatment strategy and pharmacological therapies.
https://t.co/ja4g5I9emg https://t.co/9pxeup5ACg
Dr. John Cush RheumNow ( View Tweet)
Our first TNR takes place 4/2 at 6:30pm ET and will focus on Success in Rheumatoid Arthritis. You won’t want to miss it!
https://t.co/86wJ323nwT https://t.co/WX1wBJ3yoo
Links:
Dr. John Cush RheumNow ( View Tweet)
Join our experts, Drs Liebowitz and Mehta, as they provide insights on the differential diagnosis and management concepts in autoinflammatory diseases. Sponsored by Novartis Pharmaceutical Corporation.
https://t.co/b9PNCOiL7q https://t.co/7n5DwdmaIQ
Dr. John Cush RheumNow ( View Tweet)
Higher Rates of Childlessness in Rheumatic Diseases
A Finnish population study shows that several rheumatic diseases may impair reproduction and pregnancy outcomes, with significantly higher rates of childlessness or fewer children overall for women.
https://t.co/pBoSBGGMxA https://t.co/j8RGT9qrKL
Dr. John Cush RheumNow ( View Tweet)
ACR Supports FY 2024 Budget
The ACR expressed strong support for several key measures included in the Fiscal Year (FY) 2024 budget.
https://t.co/rviB0yKxOd https://t.co/LY8AzsgWjX
Dr. John Cush RheumNow ( View Tweet)
September 2023, CDC’s recommended the updated 2023–2024 booster COVID Vaccine (monovalent XBB.1.5). MMWR study shows only 18% of high risk (immunocompromised) recv'd it. Vax was 38% effective at preventing COVID hospitalization https://t.co/vf5jkMkPwj https://t.co/c55SuIuaDb
Dr. John Cush RheumNow ( View Tweet)
GEM: Dysphagia in myositis pts is from skeletal muscle involvement, causing upper pharyngeal dysphagia, but may also manifest as dysphonia, nasal regurgitation, or aspiration (w/ risk of pneumonia). https://t.co/7UMHcX7suO
Dr. John Cush RheumNow ( View Tweet)
>25% of elderly fall each yr; falls are leading cause of injury-related death in > 65 yrs. PT & Functional exercises to improve leg strength and balance are recommended for fall prevention in @risk populations & show 20-30% less risk overall https://t.co/IPQoS4dUpS https://t.co/qUEwLX0KEq
Dr. John Cush RheumNow ( View Tweet)
57 yoBM advertising executive (w/ comorbidities) has
insidious & progressive myalgias and weakness - arms and legs; most likely Dx?
Dr. John Cush RheumNow ( View Tweet)
Wrist pain differential diagnoses beautifully demonstrated 👍 Remamber that radial-sided wrist pain is more common that ulnar-sided wrist pain. https://t.co/3Ite2FsYtl
Dr. OMID BANDARCHI OBandarchi ( View Tweet)
Predicting Vasculitis Relapse
Scores on a patient-reported sino-nasal symptom questionnaire were associated with subsequent flares of one type of ANCA-associated vasculitis (AAV), researchers said.
https://t.co/2IjrXiGbIA https://t.co/4uTsa6mc77
Dr. John Cush RheumNow ( View Tweet)
Chikungunya Arthritis - 2 studies show benefit of dexamethosone (up to 4mg/d) w/ improved DAS28 scores; Uncertain benefit however with MTX; 133 Brazilian pts studied for 5 mos & 31 pts studied for 8wks. https://t.co/Ko3aRYX0xi https://t.co/rtC4RCRjnU https://t.co/XOoFYw0dR4
Links:
Dr. John Cush RheumNow ( View Tweet)
Long term outcomes of phase III KEEPsAKE 2 trial in #PsA; SC risankizumab 150 mg given q12wks (after wk 24). 78% were ongoing. RZK achieved 60% ACR20 at wk 52, 57% ACR20 at wk 100, & 75% maintained ACR20 to wk 100. MDA achieved in 34% & 33%.https://t.co/juYQklrhG3 https://t.co/8uhmydPZDf
Dr. John Cush RheumNow ( View Tweet)